At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
- A Phase 2 Study of Pembrolizumab Immunotherapy for People With Ultra-Rare Sarcomas
Full Title URSa-1: A Minibasket Study of Pembrolizumab in Ultra-Rare Sarcomas
Purpose
Researchers are finding out if pembrolizumab immunotherapy can be useful to treat some specific types of sarcomas. The people in this study have ultra-rare sarcomas that have come back, gotten worse, or spread after treatment. The diagnoses included in this study are:
- Pleomorphic liposarcoma
- Perivascular epithelioid cell tumor (PEComa)
- Epithelioid sarcoma
- CIC-rearranged sarcoma
- Sclerosing epithelioid fibrosarcoma
Pembrolizumab takes the brakes off the immune system so immune cells can find and hopefully attack cancer cells. It is given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have one of the ultra-rare sarcoma diagnoses listed above.
- Have recurrence of the sarcoma that got worse or spread further after 1, 2, or 3 types of prior treatment.
- Have recovered from the serious side effects of previous treatments before getting pembrolizumab.
- Have not had prior immunotherapy for your sarcoma.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information about this study or to see if you can join, please call Dr. Robert Maki’s office at 646-888-5059.
Protocol
25-165Phase
Phase II (phase 2)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT07089992ClinicalTrials.gov
-
Cushing's syndrome occurs when the adrenal glands produce too much of the "stress hormone" known as cortisol. This can be caused by a tumor which develops in the pituitary gland and secretes a hormone called adrenocorticotropic hormone (ACTH). Cushing's syndrome can also be caused by an ACTH-secreting tumor elsewhere in the body, or by a tumor in the adrenal glands that makes cortisol.
-
Removal of axillary (underarm) lymph nodes to check for cancer cells is often a part of breast cancer surgery. This procedure is called axillary lymph node dissection (ALND). After ALND, some people have swelling in that arm (lymphedema).
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description. 
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
Researchers are comparing different treatments for non-muscle invasive bladder cancer (NMIBC). The people in this study have NMIBC that keeps growing after treatment with an immunotherapy called Bacillus Calmette-Guerin (BCG). They do not want surgery to remove the bladder (radical cystectomy).
-
Researchers want to see if  dietary changes can affect chemotherapy response or quality of life in people newly diagnosed with multiple myeloma. The people in this study are receiving standard induction (initial) chemotherapy with daratumumab or isatuximab, lenalidomide, bortezomib, and dexamethasone (DRVd).
-
Researchers want to find the best dose of LY3962673 that can be used safely in people with advanced solid tumors. The people in this study have tumors that have metastasized (spread) or are inoperable (cannot be taken out with surgery). They include people with colorectal cancer, non-small cell lung cancer, and pancreatic cancer.